Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 3/2011

01-12-2011

IgE, Mast Cells, and Eosinophils in Atopic Dermatitis

Authors: Fu-Tong Liu, Heidi Goodarzi, Huan-Yuan Chen

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2011

Login to get access

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease with specific immune and inflammatory mechanisms. Atopy is among the major features of the diagnosis criteria for AD but is not an essential feature. Thus, patients diagnosed with AD can be atopic or non-atopic. This review focuses on the role of IgE, mast cells, and eosinophils in the pathogenesis of AD. The known functions of IgE in allergic inflammation suggest that IgE and IgE-mediated mast cell and eosinophil activation contribute to AD, but direct evidence supporting this is scarce. The level of IgE (thus the degree of allergic sensitization) is associated with severity of AD and contributed by abnormality of skin barrier, a key feature of AD. The function of IgE in development of AD is supported by the beneficial effect of anti-IgE therapy in a number of clinical studies. The role of mast cells in AD is suggested by the increase in the mast cell number and mast cell activation in AD lesions and the association between mast cell activation and AD. It is further suggested by their role in mouse models of AD as well as by the effect of therapeutic agents for AD that can affect mast cells. The role of eosinophils in AD is suggested by the presence of eosinophilia in AD patients and eosinophil infiltrates in AD lesions. It is further supported by information that links AD to cytokines and chemokines associated with production, recruitment, and activation of eosinophils.
Literature
1.
Hanifin JM, Rajka G (1980) Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 92:44–47
2.
Williams HC (2005) Clinical practice. Atopic dermatitis. N Engl J Med 352(22):2314–2324PubMed
3.
Eichenfield LF et al (2003) Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 49(6):1088–1095PubMed
4.
Schafer T et al (1999) Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 104(6):1280–1284PubMed
5.
Laske N, Niggemann B (2004) Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol 15(1):86–88PubMed
6.
Hill DJ, Hosking CS (2004) Food allergy and atopic dermatitis in infancy: an epidemiologic study. Pediatr Allergy Immunol 15(5):421–427PubMed
7.
Illi S et al (2004) The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 113(5):925–931PubMed
8.
Wang IJ et al (2004) Correlation between age and allergens in pediatric atopic dermatitis. Ann Allergy Asthma Immunol 93(4):334–338PubMed
9.
Johnke H et al (2006) Patterns of sensitization in infants and its relation to atopic dermatitis. Pediatr Allergy Immunol 17(8):591–600PubMed
10.
Eller E et al (2009) Development of atopic dermatitis in the DARC birth cohort. Pediatr Allergy Immunol 21:307–314PubMed
11.
Kjaer HF et al (2009) The association between early sensitization patterns and subsequent allergic disease. The DARC birth cohort study. Pediatr Allergy Immunol 20(8):726–734PubMed
12.
Somani VK (2008) A study of allergen-specific IgE antibodies in Indian patients of atopic dermatitis. Indian J Dermatol Venereol Leprol 74(2):100–104PubMed
13.
Hill DJ et al (2008) Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study. Clin Exp Allergy 38(1):161–168PubMed
14.
Osterballe M et al (2009) The prevalence of food hypersensitivity in young adults. Pediatr Allergy Immunol 20(7):686–692PubMed
15.
Flohr C et al (2004) How atopic is atopic dermatitis? J Allergy Clin Immunol 114(1):150–158PubMed
16.
Johansson SG et al (2004) Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113(5):832–836PubMed
17.
Laske N, Bunikowski R, Niggemann B (2003) Extraordinarily high serum IgE levels and consequences for atopic phenotypes. Ann Allergy Asthma Immunol 91(2):202–204PubMed
18.
Wahn U et al (2008) IgE antibody responses in young children with atopic dermatitis. Pediatr Allergy Immunol 19(4):332–336PubMed
19.
Elias PM, Feingold KR (2001) Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 137(8):1079–1081PubMed
20.
O'Regan GM et al (2008) Filaggrin in atopic dermatitis. J Allergy Clin Immunol 122(4):689–693PubMed
21.
van den Oord RA, Sheikh A (2009) Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 339:b2433PubMed
22.
Leung DY et al (1993) Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 92(3):1374–1380PubMed
23.
TADA J et al (1996) Presence of specific IgE antibodies to staphylococcal enterotoxins in patients with atopic dermatitis. Eur J Dermatol 6:552–554
24.
Bunikowski R et al (1999) Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol 103(1 Pt 1):119–124PubMed
25.
Ide F et al (2004) Staphylococcal enterotoxin-specific IgE antibodies in atopic dermatitis. Pediatr Int 46(3):337–341PubMed
26.
Clark RA, Adinoff AD (1989) Aeroallergen contact can exacerbate atopic dermatitis: patch tests as a diagnostic tool. J Am Acad Dermatol 21(4 Pt 2):863–869PubMed
27.
Sanda T et al (1992) Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol 89(3):653–657PubMed
28.
Tan BB et al (1996) Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 347(8993):15–18PubMed
29.
Nolles G et al (2001) Prevalence of immunoglobulin E for fungi in atopic children. Clin Exp Allergy 31(10):1564–1570PubMed
30.
Wessels MW et al (1991) IgE antibodies to Pityrosporum ovale in atopic dermatitis. Br J Dermatol 125(3):227–232PubMed
31.
Jensen-Jarolim E et al (1992) Atopic dermatitis of the face, scalp, and neck: type I reaction to the yeast Pityrosporum ovale? J Allergy Clin Immunol 89(1 Pt 1):44–51PubMed
32.
Scalabrin DM et al (1999) Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 104(6):1273–1279PubMed
33.
Arzumanyan VG et al (2003) IgE and IgG antibodies to Malassezia spp. yeast extract in patients with atopic dermatitis. Bull Exp Biol Med 135(5):460–463PubMed
34.
Savolainen J et al (1993) Candida albicans and atopic dermatitis. Clin Exp Allergy 23(4):332–339PubMed
35.
Reefer AJ et al (2007) The relevance of microbial allergens to the IgE antibody repertoire in atopic and nonatopic eczema. J Allergy Clin Immunol 120(1):156–163PubMed
36.
Valenta R et al (1996) Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol 107(2):203–208PubMed
37.
Valenta R et al (1997) Isolation of cDNAs coding for IgE autoantigens: a link between atopy and autoimmunity. Int Arch Allergy Immunol 113(1–3):209–212PubMed
38.
Altrichter S et al (2008) Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol 128(9):2232–2239PubMed
39.
Valenta R et al (1998) Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol 111(6):1178–1183PubMed
40.
Natter S et al (1998) Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J 12(14):1559–1569PubMed
41.
Valenta R et al (1991) Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 253(5019):557–560PubMed
42.
Crameri R et al (1996) Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. J Exp Med 184(1):265–270PubMed
43.
Seiberler S et al (1999) Characterization of IgE-reactive autoantigens in atopic dermatitis. 1. Subcellular distribution and tissue-specific expression. Int Arch Allergy Immunol 120(2):108–116PubMed
44.
Novak N, Bieber T, Kraft S (2004) Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep 4(4):263–269PubMed
45.
Kolmer HL et al (1996) Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis. J Allergy Clin Immunol 98(3):702–707PubMed
46.
Spergel JM et al (1999) Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest 103(8):1103–1111PubMed
47.
MacGlashan DW Jr et al (1997) Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158(3):1438–1445PubMed
48.
Beck LA et al (2004) Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 114(3):527–530PubMed
49.
Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53(2):338–340PubMed
50.
Beck LA, Saini S (2006) Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 55(3):540–541, author reply 541–2PubMed
51.
Lane JE et al (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54(1):68–72PubMed
52.
Vigo PG et al (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168–170PubMed
53.
Belloni B et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120(5):1223–1225PubMed
54.
Forman SB, Garrett AB (2007) Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis 80(1):38–40PubMed
55.
Incorvaia C et al (2008) Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 69(2):78–80PubMed
56.
Sheinkopf LE et al (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29(5):530–537PubMed
57.
Walsh LJ et al (1991) Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 88(10):4220–4224PubMed
58.
Schleimer RP et al (1992) IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 148(4):1086–1092PubMed
59.
Sironi M et al (1994) Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood 84(6):1913–1921PubMed
60.
Nakae S et al (2006) Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 176(4):2238–2248PubMed
61.
Nakae S et al (2005) Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci USA 102(18):6467–6472PubMed
62.
Mekori YA, Metcalfe DD (1999) Mast cell–T cell interactions. J Allergy Clin Immunol 104(3 Pt 1):517–523PubMed
63.
Tkaczyk C et al (1996) Mouse bone marrow-derived mast cells and mast cell lines constitutively produce B cell growth and differentiation activities. J Immunol 157(4):1720–1728PubMed
64.
Pawankar R et al (1997) Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 99(7):1492–1499PubMed
65.
Gauchat JF et al (1993) Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365(6444):340–343PubMed
66.
Kohda F et al (2002) Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-gamma and IL-4 in human keratinocytes. J Dermatol Sci 28(1):34–41PubMed
67.
Kanda N, Watanabe S (2004) Histamine enhances the production of granulocyte-macrophage colony-stimulating factor via protein kinase C alpha and extracellular signal-regulated kinase in human keratinocytes. J Invest Dermatol 122(4):863–872PubMed
68.
Ioffreda MD, Whitaker D, Murphy GF (1993) Mast cell degranulation upregulates alpha 6 integrins on epidermal Langerhans cells. J Invest Dermatol 101(2):150–154PubMed
69.
Jawdat DM et al (2004) IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J Immunol 173(8):5275–5282PubMed
70.
Suto H et al (2006) Mast cell-associated TNF promotes dendritic cell migration. J Immunol 176(7):4102–4112PubMed
71.
Mazzoni A et al (2006) Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol 177(6):3577–3581PubMed
72.
Theiner G, Gessner A, Lutz MB (2006) The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo. Immunobiology 211(6–8):463–472PubMed
73.
Frandji P et al (1993) Antigen-dependent stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J Immunol 151(11):6318–6328PubMed
74.
Fox CC, Jewell SD, Whitacre CC (1994) Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell Immunol 158(1):253–264PubMed
75.
Frandji P et al (1995) Presentation of soluble antigens by mast cells: upregulation by interleukin-4 and granulocyte/macrophage colony-stimulating factor and downregulation by interferon-gamma. Cell Immunol 163(1):37–46PubMed
76.
Frandji P et al (1996) Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Eur J Immunol 26(10):2517–2528PubMed
77.
Malaviya R et al (1996) Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol 156(4):1490–1496PubMed
78.
Soter NA (1989) Morphology of atopic eczema. Allergy 44(Suppl 9):16–19PubMed
79.
Irani AM, Sampson HA, Schwartz LB (1989) Mast cells in atopic dermatitis. Allergy 44(Suppl 9):31–34PubMed
80.
Groneberg DA et al (2005) Mast cells and vasculature in atopic dermatitis—potential stimulus of neoangiogenesis. Allergy 60(1):90–97PubMed
81.
Cox HE et al (1998) Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptor. Br J Dermatol 138(1):182–187PubMed
82.
Mao XQ et al (1996) Association between genetic variants of mast-cell chymase and eczema. Lancet 348(9027):581–583PubMed
83.
Badertscher K et al (2005) Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol Res 296(10):503–506PubMed
84.
Zhao L et al (2006) A rodent model for allergic dermatitis induced by flea antigens. Vet Immunol Immunopathol 114(3–4):285–296PubMed
85.
Kanbe T et al (2001) Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity. Br J Dermatol 144(6):1148–1153PubMed
86.
Ring J, Thomas P (1989) Histamine and atopic eczema. Acta Derm Venereol Suppl Stockh 144:70–77PubMed
87.
Hamid Q et al (1996) In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 98(1):225–231PubMed
88.
Hamid Q, Boguniewicz M, Leung DY (1994) Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94(2):870–876PubMed
89.
Horsmanheimo L et al (1994) Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 131(3):348–353PubMed
90.
Steinhoff M et al (2003) Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 23(15):6176–6180PubMed
91.
Gombert M et al (2005) CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol 174(8):5082–5091PubMed
92.
Groneberg DA et al (2003) Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol 111(5):1099–1105PubMed
93.
Lewis RA, Austen KF (1981) Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature 293(5828):103–108PubMed
94.
Fischer M et al (2006) Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Investig 116(10):2748–2756PubMed
95.
Kawakami T et al (2009) Mast cells in atopic dermatitis. Curr Opin Immunol 21:666–678PubMed
96.
Chan LS, Robinson N, Xu LT (2001) Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Investig Dermatol 117(4):977–983PubMed
97.
Zheng T et al (2009) Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 129(3):742–751PubMed
98.
Morioka T et al (2009) IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Br J Dermatol 160(6):1172–1179PubMed
99.
Tam SY et al (2004) RabGEF1 is a negative regulator of mast cell activation and skin inflammation. Nat Immunol 5(8):844–852PubMed
100.
Alenius H et al (2002) Mast cells regulate IFN-gamma expression in the skin and circulating IgE levels in allergen-induced skin inflammation. J Allergy Clin Immunol 109(1):106–113PubMed
101.
Matsuda H et al (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9(3):461–466PubMed
102.
Matsuoka H et al (2003) A mouse model of the atopic eczema/dermatitis syndrome by repeated application of a crude extract of house-dust mite Dermatophagoides farinae. Allergy 58(2):139–145PubMed
103.
Terada M et al (2006) Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. Proc Natl Acad Sci USA 103(23):8816–8821PubMed
104.
Terakawa M et al (2008) Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis. Eur J Pharmacol 601(1–3):186–191PubMed
105.
Watanabe N et al (2002) Chymase inhibitor improves dermatitis in NC/Nga mice. Int Arch Allergy Immunol 128(3):229–234PubMed
106.
Kim Y et al (2008) Hyaluronic acid targets CD44 and inhibits FcepsilonRI signaling involving PKCdelta, Rac1, ROS, and MAPK to exert anti-allergic effect. Mol Immunol 45(9):2537–2547PubMed
107.
Schleimer RP et al (1983) Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest 71(6):1830–1835PubMed
108.
Smith SJ et al (2002) Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin Exp Allergy 32(6):906–913PubMed
109.
Kato A et al (2009) Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells. J Immunol 182(11):7233–7243PubMed
110.
Gisondi P, Ellis CN, Girolomoni G (2005) Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract 59(8):969–974PubMed
111.
Sardy M, Ruzicka T, Kuhn A (2009) Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 301(1):93–98PubMed
112.
Simon D et al (2004) Reduced dermal infiltration of cytokineexpressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 114(4):887–895PubMed
113.
Denburg JA et al (1985) Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 66(2):312–318PubMed
114.
Young B (2006) Wheater’s functional histology: a text and colour atlas, 5th edn. Churchill Livingstone/Elsevier, Edinburgh, p 437
115.
Leiferman KM (1991) A current perspective on the role of eosinophils in dermatologic diseases. J Am Acad Dermatol 24(6 Pt 2):1101–1112PubMed
116.
Zheutlin LM et al (1984) Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 133(4):2180–2185PubMed
117.
Moy JN, Gleich GJ, Thomas LL (1990) Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol 145(8):2626–2632PubMed
118.
Rohrbach MS et al (1990) Activation of platelets by eosinophil granule proteins. J Exp Med 172(4):1271–1274PubMed
119.
Kita H et al (1995) Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 154(9):4749–4758PubMed
120.
Kato M et al (1998) Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 252(3):418–425PubMed
121.
Kagi MK, Joller-Jemelka H, Wuthrich B (1992) Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology 185(2):88–92PubMed
122.
Uehara M, Izukura R, Sawai T (1990) Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol 15(4):264–266PubMed
123.
Nishimoto M et al (1998) Peripheral eosinophil counts relates the improvement of the skin lesions of atopic dermatitis patients more sensitive than serum eosinophil cationic protein levels. Arerugi 47(6):591–596PubMed
124.
Borres MP, Bjorksten B (2004) Peripheral blood eosinophils and IL-4 in infancy in relation to the appearance of allergic disease during the first 6 years of life. Pediatr Allergy Immunol 15(3):216–220PubMed
125.
Leiferman KM et al (1985) Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med 313(5):282–285PubMed
126.
Leiferman KM (2001) A role for eosinophils in atopic dermatitis. J Am Acad Dermatol 45(1 Suppl):S21–S24PubMed
127.
Pucci N et al (2000) Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 105(2 Pt 1):353–357PubMed
128.
Breuer K, Kapp A, Werfel T (2001) Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis of the adult age. Allergy 56(8):780–784PubMed
129.
Goto T et al (2007) Urinary eosinophil-derived neurotoxin concentrations in patients with atopic dermatitis: a useful clinical marker for disease activity. Allergol Int 56(4):433–438PubMed
130.
Czech W et al (1992) Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Dermatol 126(4):351–355PubMed
131.
Wassom DL et al (1981) Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 67(3):651–661PubMed
132.
Taniuchi S et al (2001) Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci 26(1):79–82PubMed
133.
Oymar K, Bjerknes R (2000) Urinary eosinophil protein X in children with atopic dermatitis: relation to atopy and disease activity. Allergy 55(10):964–968PubMed
134.
Halmerbauer G, Frischer T, Koller DY (1997) Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 52(7):765–769PubMed
135.
Caproni M et al (1996) Modulation of serum eosinophil cationic protein levels by cyclosporin in severe atopic dermatitis. Br J Dermatol 135(2):336–337PubMed
136.
Bradding P et al (1994) Interleukin-4, −5, and −6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 10(5):471–480PubMed
137.
Nishinakamura R et al (1996) Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 88(7):2458–2464PubMed
138.
Simon D, Braathen LR, Simon HU (2004) Eosinophils and atopic dermatitis. Allergy 59(6):561–570PubMed
139.
Yamaguchi Y et al (1988) Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 167(5):1737–1742PubMed
140.
Rothenberg ME, Hogan SP (2006) The eosinophil. Annu Rev Immunol 24:147–174PubMed
141.
Yamamoto N et al (2003) Heterogeneity of interleukin 5 genetic background in atopic dermatitis patients: significant difference between those with blood eosinophilia and normal eosinophil levels. J Dermatol Sci 33(2):121–126PubMed
142.
Amerio P et al (2003) Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Curr Drug Targets Inflamm Allergy 2(1):81–94PubMed
143.
Nonaka M et al (2004) Induction of eotaxin production by interleukin-4, interleukin-13 and lipopolysaccharide by nasal fibroblasts. Clin Exp Allergy 34(5):804–811PubMed
144.
Teixeira MM et al (1997) Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest 100(7):1657–1666PubMed
145.
Chihara J (1998) The role of chemokines such as RANTES in allergic disease. Rinsho Byori 46(8):816–820PubMed
146.
Oyamada H et al (2006) RANTES production from mononuclear cells in response to the specific allergen in asthma patients. Allergol Int 55(3):253–259PubMed
147.
Masuda K et al (2003) Increased levels of serum interleukin-16 in adult type atopic dermatitis. Acta Derm Venereol 83(4):249–253PubMed
148.
Grewe M et al (1998) Human eosinophils produce biologically active IL-12: implications for control of T cell responses. J Immunol 161(1):415–420PubMed
149.
Kang K, Stevens SR (2003) Pathophysiology of atopic dermatitis. Clin Dermatol 21(2):116–121PubMed
150.
Elovic A et al (1994) Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol 93(5):864–869PubMed
151.
Phipps S et al (2002) The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol 169(8):4604–4612PubMed
Metadata
Title
IgE, Mast Cells, and Eosinophils in Atopic Dermatitis
Authors
Fu-Tong Liu
Heidi Goodarzi
Huan-Yuan Chen
Publication date
01-12-2011
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2011
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-011-8252-4

Other articles of this Issue 3/2011

Clinical Reviews in Allergy & Immunology 3/2011 Go to the issue

ReviewPaper

Innate Immunity in Atopic Dermatitis

ReviewPaper

Atopic Dermatitis: New Trends and Perspectives

ReviewPaper

Role of Dendritic Cells in Atopic Dermatitis: An Update

ReviewPaper

Therapeutic Perspectives in Atopic Dermatitis

ReviewPaper

A Modular View of Cytokine Networks in Atopic Dermatitis

ReviewPaper

Atopic Dermatitis and the Nervous System
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits